AccurEdit Therapeutics
PrivateLast Round
Series A
Sep 1, 2025
Est. Valuation
$147M
Total Funding Raised
$116M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
AccurEdit Therapeutics operates in Healthcare & Life Sciences and is based in Jiangsu. Its latest recorded funding round was a Series A round in September 2025.
AccurEdit Therapeutics is a biotechnology company that develops in vivo gene editing therapies and delivery technologies for the treatment of severe or life-threatening genetic and acquired diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AccurEdit Therapeutics Comparables
Compare AccurEdit Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shape Therapeutics | 84% | |
| AIRNA | 81% | |
| Frequency Therapeutics | 79% |
For institutional investors. Book with your work email.
AccurEdit Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 1, 2025 | ||||
| Seed | Sep 1, 2021 |
For institutional investors. Book with your work email.
AccurEdit Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cormorant Asset Management | Seed |
| Legend Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 448% MoM, reaching 3.3K.
- Jul 13, 2026
Open roles increased to 71, 592% of headcount.
For institutional investors. Book with your work email.
AccurEdit Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AccurEdit Therapeutics's valuation, stock price, and market status.
Is AccurEdit Therapeutics a public or private company?
AccurEdit Therapeutics is a private company.
What is the current stock price of AccurEdit Therapeutics?
AccurEdit Therapeutics is a private company, so its shares have no public market price. Caplight tracks AccurEdit Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AccurEdit Therapeutics worth (valuation)?
AccurEdit Therapeutics's valuation is estimated at $147.0M based on funding round data.
Can I buy AccurEdit Therapeutics stock?
AccurEdit Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AccurEdit Therapeutics's last funding round?
AccurEdit Therapeutics's most recent funding round was Series A on September 1, 2025.
Who are the main investors in AccurEdit Therapeutics?
Key investors in AccurEdit Therapeutics include Legend Capital.
Will AccurEdit Therapeutics IPO soon?
No public IPO plans have been announced for AccurEdit Therapeutics.
How can I track AccurEdit Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in AccurEdit Therapeutics's shares on secondary markets.